Gilead, Merck: Lung Cancer Setback, HIV Win

Gilead Sciences and Merck announced they are ending a Phase 3 clinical trial testing Gilead's Trodelvy in combination with Merck's Keytruda for a type of lung cancer. The trial was stopped because, while the drug combo showed some improvement in delaying cancer progression, the result was not statistically significant. The companies concluded that the study was unlikely to show a meaningful survival benefit for patients in the final analysis.

Separately, the two companies reported positive news from a different program. Their investigational once-weekly oral HIV regimen, combining the drugs islatravir and lenacapavir, successfully met its primary goals in two late-stage Phase 3 trials.

In the first HIV study, patients who switched from the popular daily pill Biktarvy to the new weekly regimen maintained viral suppression just as effectively. The second study showed the weekly pill was also non-inferior to other standard daily HIV treatments.

The safety profile for the new HIV combination was consistent with what was already known about the drugs, with no new safety concerns raised in either trial. Detailed data from both the halted cancer trial and the successful HIV studies will be presented at future medical conferences.

Following the HIV trial success, Gilead and Merck plan to submit the data to health regulators around the world, aiming for approval of what could be the first once-weekly oral pill for HIV.

For Gilead, the termination of the Trodelvy-Keytruda lung cancer trial is a significant clinical and commercial setback. Trodelvy is a key growth driver for Gilead beyond its HIV franchise, and expanding its use into major cancers like lung cancer was a high-priority goal. This failure narrows Trodelvy's potential market and may dampen investor enthusiasm for its near-term growth prospects, which is reflected in the stock's decline on the news.

The successful HIV trial results, however, provide a crucial counterbalance, especially for Gilead. As the dominant player in HIV treatment, Gilead is under constant pressure to innovate and defend its market share. A convenient, once-weekly oral pill could be a blockbuster product, helping the company retain patients and stay ahead of competitors. For Merck, the HIV success adds a promising asset to its pipeline with relatively lower risk, as it partners with the market leader.

This news perfectly illustrates the binary nature of biotech investing. A single trial result can dramatically alter a drug's commercial potential and a company's valuation. Investors must weigh the high risk of failure in new cancer indications against the steadier, but competitive, path of developing next-generation therapies for established markets like HIV.

The market's immediate reaction—Gilead's stock fell while Merck's rose slightly—suggests investors see Gilead bearing more of the downside from the cancer trial halt, while Merck benefits from the shared HIV win without a major pipeline setback of its own. The long-term impact will depend on the commercial potential of the weekly HIV pill versus the lost opportunity in lung cancer.